American pharma giants are increasingly turning to Chinese labs to discover, test and develop cutting-edge drugs. On today’s Big Take Asia podcast, Bloomberg’s Amber Tong and Robert Langreth join Oanh Ha to break down why global drugmakers are sourcing their next big breakthroughs from China — and what that means for US biotech dominance. Read more: Big Pharma Is Hooked on Chinese Licensing Deals Hosted by K. Oanh Ha; Produced by Naomi Ng and David Fox; Guests: Amber Tong and Robert Langreth; Edited by Paddy Hirsch and Crispina Robert. Fact-checking by Brunella Tipismana Urbano; Engineering by Alex Suguira. Senior Producer: Naomi Shavin; Deputy Executive Producer: Julia Weaver. Executive Producer: Nicole Beemsterboer.See omnystudio.com/listener for privacy information.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Big Take Asia
Japan Hikes Rates, Reshaping Carry Trade
Is the US AI Reckoning an Opportunity for China?
How India Is Training the Robots of the Future
Deadly Flooding in Nepal Highlights Asia’s Climate Vulnerability
Get summaries like this every morning.
Free AI-powered recaps of Big Take Asia and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.